Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Orion Oyj

News headline image
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
From Orion Oyj
Via GlobeNewswire
News headline image
Orion to open new Biologics R&D Centre in Cambridge, UK in 2025 to support global growth strategy, considers reorganizing some work in Turku
From Orion Oyj
Via GlobeNewswire
News headline image
EU’s Urban Wastewater Treatment Directive could lead to additional costs of nearly EUR 1 billion in Finland alone, posing a serious threat to medicine availability
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and Invenra announce discovery service and commercial license agreement to develop innovative bispecific antibody cancer therapeutics
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and Abilita Therapeutics announce research collaboration and option to license agreement to develop innovative antibody therapeutics
From Orion Oyj
Via GlobeNewswire
News headline image
Inside information: Orion terminates ODM-111 development program due to narrow therapeutic window of the molecule
From Orion Oyj
Via GlobeNewswire
News headline image
Orion’s collaboration partner Bayer submits application to U.S. FDA for third indication of darolutamide which has become the first ever Orion-originated blockbuster
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and Aitia enter AI-Driven Drug Discovery and Drug Simulation Collaboration in Oncology
From Orion Oyj
Via GlobeNewswire
News headline image
Darolutamide plus androgen deprivation therapy significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT in patients with metastatic hormone-sensitive prostate cancer
From Orion Oyj
Via GlobeNewswire
News headline image
Inside information: Phase III ARANOTE trial of darolutamide in combination with androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer meets primary endpoint
From Orion Oyj
Via GlobeNewswire
News headline image
Inside information: Orion and MSD Announce Mutual Exercise of Option Providing MSD Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
From Orion Oyj
Via GlobeNewswire
News headline image
Orion is developing the Finnish life science industry in a unique collaboration project
From Orion Oyj
Via GlobeNewswire
News headline image
Additional ODM-208/MK-5684 Phase II data presented at ASCO-GU 2024
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and MSD Announce Initiation of Two Phase 3 Trials Evaluating ODM-208/MK5684 in Certain Patients with Metastatic Castration-Resistant Prostate Cancer
From Orion Oyj
Via GlobeNewswire
News headline image
NEJM Evidence publishes results from Phase I/IIa CYPIDES trial with ODM-208
From Orion Oyj
Via GlobeNewswire
News headline image
Orion Research Foundation grants EUR 1,112,000 for research in 2024
From Orion Oyj
Via GlobeNewswire
News headline image
European Commission approval of Ztalmy® (ganaxolone) for the adjunctive treatment of epileptic seizures associated with CDKL5 deficiency disorder
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and Bayer expand clinical development program for darolutamide in prostate cancer
From Orion Oyj
Via GlobeNewswire
News headline image
Darolutamide approved for additional prostate cancer indication in China
From Orion Oyj
Via GlobeNewswire
News headline image
Darolutamide receives EU approval for additional indication in prostate cancer
From Orion Oyj
Via GlobeNewswire
News headline image
Darolutamide receives approval for additional prostate cancer indication in Japan
From Orion Oyj
Via GlobeNewswire
News headline image
Positive CHMP opinion for darolutamide in combination with docetaxel for the treatment of metastatic hormone-sensitive prostate cancer
From Orion Oyj
Via GlobeNewswire
News headline image
Orion and Amneal enter strategic partnership – Orion receives exclusive licence to commercialise Amneal’s generic products in Europe, Australia and New Zealand
From Orion Oyj
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.